Chemomab Therapeutics Ltd. financial data

Symbol
CMMB on Nasdaq
Industry
Pharmaceutical Preparations
Location
Kiryat Atidim, Building 7, Tel Aviv, Israel
State of incorporation
Israel
Fiscal year end
December 31
Former names
Anchiano Therapeutics Ltd. (to 3/17/2021), BioCancell Ltd. (to 11/3/2015)
Latest financial report
20-F - Q4 2024 - Apr 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 583 % -70.7%
Debt-to-equity 20.2 % +264%
Return On Equity -101 % -209%
Return On Assets -84.2 % -172%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 377M shares +32.7%
Common Stock, Shares, Outstanding 287M shares +15.8%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 286M shares +29.1%
Weighted Average Number of Shares Outstanding, Diluted 286M shares +29.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.93M USD -41.7%
General and Administrative Expense 840K USD -73.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.63M USD +54.2%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -3.63M USD +54.4%
Earnings Per Share, Basic 0.01 USD/shares -55.6%
Earnings Per Share, Diluted 0.01 USD/shares -55.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.07M USD -34.7%
Cash, Cash Equivalents, and Short-term Investments 14.3M USD
Assets, Current 16M USD -23.2%
Property, Plant and Equipment, Net 250K USD -17.5%
Operating Lease, Right-of-Use Asset 289K USD -26.3%
Assets 17M USD -23.4%
Employee-related Liabilities, Current 874K USD +6.2%
Accrued Liabilities, Current 1.56M USD -54.3%
Liabilities, Current 3.22M USD -33.5%
Operating Lease, Liability, Noncurrent 209K USD -33.9%
Liabilities 3.43M USD -33.5%
Retained Earnings (Accumulated Deficit) -103M USD -15.7%
Stockholders' Equity Attributable to Parent 13.5M USD -20.4%
Liabilities and Equity 17M USD -23.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.19M USD -93.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 14.4M USD +506%
Common Stock, Shares Authorized 4.65B shares +615%
Common Stock, Shares, Issued 377M shares +32.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7.25M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.15M USD -34.4%
Deferred Tax Assets, Valuation Allowance 44.2M USD +1.72%
Deferred Tax Assets, Gross 44.2M USD +1.72%
Operating Lease, Liability 324K USD -17.3%
Depreciation 16K USD +23.1%
Payments to Acquire Property, Plant, and Equipment 1K USD -92.9%
Lessee, Operating Lease, Liability, to be Paid 346K USD -25.4%
Property, Plant and Equipment, Gross 529K USD 0%
Operating Lease, Liability, Current 115K USD +51.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 120K USD +4.35%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 22K USD -69.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 120K USD -0.83%
Deferred Tax Assets, Operating Loss Carryforwards 40.8M USD +6.53%
Lessee, Operating Lease, Liability, to be Paid, Year Four 106K USD -12.4%
Additional Paid in Capital 116M USD +9.92%
Deferred Tax Assets, Net of Valuation Allowance 0 USD